N/A N=55 Role of microRNAs in T Cell-Driven Inflammation in Asthma
Asthma
Primary: Difference in Baseline T Cell miRNA Expression Between Asthmatics and Healthy Controls — 13.2; 10.2; 13.6; 11.7 Normalized log2 copy number — p=0.32
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=439 Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women
Alcohol; Harmful Use · Binge Drinking · Risk Behavior
Primary: Change in Alcohol Use (Heavy Drinking Days) — 6; 6; 6; 3 heavy drinking days
Phase 2 N=38 ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Lateral Canthal Lines, LCL · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…
Phase 3 N=1,057 A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Multiple Sclerosis
Primary: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 519; 212; 207; 69 Participants
N/A N=30 Pleth Variability Index (PVI) as a Measure of Volume Status During Transcatheter Mitral Valve Repair
Mitral Regurgitation
Primary: Delta PVI to Delta LAP Correlation During MitraClip Placement — 4.30; -26.14 percentage of baseline (pre-MitraClip) — p=0.066
Phase 2 N=11 A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 2 Participants
Phase 4 N=91 A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™
Hepatitis B
Primary: Seroprotection Rate Achieved One Month After the Third Immunization With Sci-B-Vac™. — 83 Participants
N/A N=91 AMPLATZER™ Cardiac Plug Observational Post-Approval Study
Non-valvular Atrial Fibrillation (NVAF)
Primary: Short-Term Safety Endpoint: Composite Rate of Death, Stroke, Systemic Embolism, and Procedure or Device-related Complications Requiring Intervention — 1.1 percentage of…
N/A N=99 ivWatch Sensor: Device Validation for Infiltrated Tissues
Infiltration of Peripheral IV Therapy
Primary: Red Notification Sensitivity to Infiltrated Tissues — 99.0; 99.0 percentage of infiltrations detected
Phase 2 N=75 Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Actinic Keratosis
Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions
Phase 3 N=201 A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults
Hepatitis B
Primary: Percentage of Participants With an Antibody Response (≥10 IU/Liter) to Hepatitis B Surface Antigens One Month After the Third Vaccination — 120; 115; 109 Participants
Phase 2 N=25 Decitabine and Talazoparib in Untreated AML and R/R AML
Acute Myeloid Leukemia
Primary: Phase 1 - Dose Finding — 10; 15; 20; 20 mg/m^2
Phase 2 N=117 Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -2.04; -2.00 score on a scale
N/A N=61 Virtual Reality Treatment for Adults With Chronic Back Pain
Chronic Pain · Back Pain Lower Back Chronic · Back Pain
Primary: Change in Pain Intensity and Interference. — -1.5; -0.5 units on a scale — p=0.014
Phase 2 N=136 Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
Obesity
Primary: Gastric Emptying of Solids (T1/2) — 191.6; 105.9 minutes